In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. Human epidermal growth factor receptor 2 (HER2) tests, using biopsied tissue, typically breast tissue, are carried out to detect over-expression of the HER2 protein, or additional copies HER2/neu gene encoding for the protein; the outcome of which may guide therapies to treat certain breast cancers, along with some ovarian cancers uterine cancers, stomach cancers, and lung cancers. GlobalData uses proprietary data and analytics to provide a comprehensive report on the her2 amplification tests market in Finland. Buy the latest report here.
Smarter leaders trust GlobalData
In 2022, GlobalData’s Market Model methodology determined that the leading player in the her2 amplification tests market in Finland was Abbott Laboratories followed by Agilent Technologies, Biocare Medical, Danaher, F. Hoffmann-La Roche, Illumina, medac, Merck, New England Biolabs, Qiagen, Sysmex and Thermo Fisher Scientific.
Understanding market size can be crucial to evaluate opportunities and make informed decisions about market entry and exit. Medical device companies can identify attractive segments in respective markets as well as develop marketing strategies based on forecasts for those segments.
HER Tests includes Immunohistochemistry (IHC) Tests, In Situ Hybridization (ISH) Tests, and Comparative genomic Hybridization (aCGH) Tests.
The her2 amplification tests market in Finland can expand or contract due to a variety of reasons including population demographics, disease incidence and prevalence, macroeconomic issues, and geopolitical considerations. Disruption to a market could be caused by a sudden, unexpected change in these factors, but it could also be driven by changes in clinical practice, leading to a change in diagnosis or treatment of patients, as part of a process to generally improve medical practice.
For the latest analysis of the market size her2 amplification tests in Finland, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Medical Intelligence Center Market Models are the gold standard of medical device market valuation, company share estimation and market trend forecasting. GlobalData uses a patient-based forecast model or installed base methodology to determine the market size for therapeutic indications and capital equipment expenditures. Estimates are based on a number of sources, including primary research—KOL and industry contact interviews—and secondary research, such as company reports, press releases, published articles, proprietary databases, and general news media.
